Concepedia

Author

I. Judson

Royal Marsden Hospital

Also Known As

I Judson, I R Judson, I. Judson, I. R. Judson, I.R. Judson, IR Judson, Ian Judson, JUDSON, IR, Judson, I, Judson, IR

50

Publications

783

Citations

12

H-Index

49

Concepts

All Affiliations

Royal Marsden HospitalInstitute of Cancer Research
IJ

About

I. Judson is an author at Royal Marsden Hospital specializing in pharmacology, medicine, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

294

2

Health Sciences

4

4

118

3

Biochemistry

1

1

25

4

Biomolecular Engineering

1

1

12

5

Cell Biology

1

1

26

I. Judson

×

11

Publications

304

Citations

10

H-Index

YearCitations

Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

Hilary Calvert, I. Judson, W J van der Vijgh

PubMed

1993

80

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

D C Talbot, Ian E. Smith, Janine Mansi,

Journal of Clinical Oncology

1991

62

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer

TJ Powles, A.L Jones, I. Judson,

British Journal of Cancer

1991

34

The contemporary drug development process: advances and challenges in preclinical and clinical development.

Garrett Garrett, I. Judson, Paul Workman

PubMed

2003

26

Metabolites of 2'-fluoro-2'-deoxy-D-glucose detected by 19F magnetic resonance spectroscopy in vivo predict response of murine RIF-1 tumors to 5-fluorouracil.

Paul M.J. McSheehy, Martin O. Leach, I. Judson,

PubMed

2000

25

73 POSTER Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients

Peter Stopfer, Willy Roth, K. Mross,

European Journal of Cancer Supplements

2006

17

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies

C. P. Lee, Gerhardt Attard, L. Poupard,

Journal of Clinical Oncology

2005

15

A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours

Elizabeth Ruth Plummer, Hilary Calvert, Hendrik-Tobias Arkenau,

Journal of Clinical Oncology

2008

13

Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks

José Trigo, Clarence E. Rees, Philip Beale,

European Journal of Cancer

1999

12

Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum[II])

Lloyd R. Kèlland, I. Judson, María Koehler,

Lung Cancer

2000

10

Page 1